logo
Gloves do not replace hand hygiene: WHO

Gloves do not replace hand hygiene: WHO

Time of India07-05-2025

Gloves look like the ultimate hygiene hack
Most of us never thought twice about hand gloves until the pandemic turned them into a must-have accessory right next to masks and hand sanitizers. But even now, gloves continue to play a quiet but powerful role in reducing infections, especially in medical, caregiving, and food-handling settings. Think of gloves as your first line of defense—blocking direct contact with germs, viruses, and nasty bacteria lurking on surfaces, body fluids, or even raw food. For healthcare workers, gloves aren't optional—they're lifesavers, literally.Gloves have gone mainstream. From salons to street vendors, people are using them more consciously to avoid cross-contamination. The awareness that dirty hands spread everything from colds to E. coli has stuck with us post-COVID, and that's a good thing. The popularity of gloves, especially disposable nitrile and latex ones, has skyrocketed—not just as protective gear but as a signal that someone's taking hygiene seriously.However, WHO has said that gloves do not replace hand hygiene. "While medical gloves serve a vital role in preventing transmission of infection, for example when there is risk of exposure to blood and body fluids, they are not a substitute for cleaning hands at the right time," the World Health Organisation (WHO) has said on World Hand Hygiene Day.'Medical gloves can reduce the risk of infection, but they are never a replacement for hand hygiene,' said Dr Bruce Aylward, WHO Assistant Director-General, Universal Health Coverage, Life Course. 'On this World Hand Hygiene Day, let us double down on our commitment and action to improve hand hygiene in health care settings to ensure the safety of patients and health-care workers.'"Additionally, overuse of gloves contributes to environmental degradation," the WHO report said. "An average university hospital in a developed country generates 1634 tons of health-care waste each year, which is equivalent to over 360 African elephants. Much of the waste could have been avoided if gloves were used properly and good hand hygiene was practiced. Most used gloves are considered infectious and require high-temperature incineration or specialized treatment, adding strain to already burdened waste management systems," it adds.You slip them on, and boom—you feel safe from germs. And yes, gloves absolutely have their place. In hospitals, labs, and even your kitchen, they offer a solid layer of protection against infections. But here's the not-so-glamorous truth: gloves aren't foolproof, and they're definitely not problem-free. First off, just wearing gloves doesn't make you immune to spreading germs. In fact, gloves can give a false sense of security. People often touch everything—phones, doorknobs, their face—with gloves on, thinking they're protected. But if the gloves pick up germs and you rub your eye or scratch your nose? You're still exposed. It's like wearing muddy shoes and walking all over your clean floor.Then there's the issue of cross-contamination. Gloves can transfer bacteria just as easily as bare hands if you're not careful. Ever seen someone wear the same pair of gloves for hours? Yup, not helping. And let's not forget about allergies and skin irritation—especially from latex gloves. Plus, overusing gloves can actually damage the skin underneath, making it dry and more prone to tiny cuts, which opens the door to—you guessed it—infection.Gloves are a helpful tool, but they're not a substitute for good hygiene. Wash your hands. Change gloves often. Don't touch your face. And remember—clean hands, not just covered hands, are your best defense.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Talent loss a major threat to addressing global AMR crisis
Talent loss a major threat to addressing global AMR crisis

Hindustan Times

time37 minutes ago

  • Hindustan Times

Talent loss a major threat to addressing global AMR crisis

Antimicrobial resistance (AMR) is turning out to be one of the major health calamities, with two million deaths projected to occur in India alone by 2025 and 10 million globally. While the discovery of penicillin in 1928, revolutionised the field of medicine and saved millions of lives, the industry has witnessed a constant decline in the development of new antibiotics ever since then. The lack of resources and high investments are the widely considered reasons for this gap, but one key aspect that remains largely overlooked is the loss of potent scientific and research talent for more than two decades. In an in-depth research report, Leaving the Lab, AMR Industry Alliance highlights alarming data on this brain drain phenomenon. According to the study, research and development (R&D) workforce is limited with approximately 3,000 AMR researchers currently active in the world, compared to around 46,000 for cancer and 5,000 for HIV/AIDS. Meanwhile, the total number of authors on all AMR publications declined from a high of 3,599 in 1995 to just 1,827 in 2020. Investigators with a focused research interest in AMR too have further declined since the mid-1990s, falling from a peak of 1,300 to less than 700 by 2020. The situation is even more worrisome in the context of India. According to the World Health Organization (WHO), India contributes only 1% to the global antibacterial R&D pipeline, whereas 84% of this research is concentrated in high-income countries, with another 12% in upper-middle-income economies. For a country like India which not only carries one of the world's highest burdens of AMR but also contributes meaningfully to AMR resistance on the global level, the lack of focus on research and innovation severely undermines the efforts to combat this threat. The 2016 UNGA High-Level Meeting on AMR discussed a number of actions, including talent loss to address these challenges globally. However, the industry is still witnessing slow progress on work to contain AMR. This brain drain could further exacerbate the situation if necessary steps aren't taken to tackle the crisis at hand. This current trajectory of AMR research is deeply troubling and stems from a fundamental market failure. Currently most of the private investors and governments prefer directing fund to research in other disease areas, creating a vacuum for companies and SMEs who actively want to amplify work in the field of AMR. And even if some of the biggest players in the market invest in creating new antibiotics, they often don't attract investment. In recent years, AstraZeneca, Novartis, and Johnson & Johnson have all exited or cut back their work on AMR, including closing R&D facilities, selling antimicrobial portfolios, ending AMR development, and letting go of research teams. While SMEs are more agile and innovative in early-stage research and development of antibiotics in comparison to the bigger players, their situation too is marred by lack of funding globally. According to a report by the BEAM Alliance, 54% of the SME members struggle with enough funds to cover even a year's worth of operations and fear bankruptcy. Biopharmaceutical company, Achaogen is a prime example. Even after securing US FDA approval for plazomicin, the company was still forced to declare bankruptcy in April 2019 – after spending nearly a billion dollars and over a decade developing the antibiotic. This phenomenon further exacerbates the broken market for antimicrobials where major pharmaceutical companies are unable to offer long-term careers as they either fear bankruptcy or lack of investments and funding to continue research. On the incentives front, clinicians in antimicrobial and antifungal R&D teams face significant pay gaps when compared to fellowships across all other specialties. In 2022, 44% of infectious disease fellowships went unfilled in the US – more than double the proportion of unfilled fellowships across all specialties. A 2022 Medscape report showed a pay gap of $4,000 between infectious disease doctors and internal medicine doctors across the US, despite the additional years of training and debt required. While India has made commendable strides in public health in the recent years, AMR continues to represent an unprecedented challenge--it can't be resolved by treatment alone. As the most populated country across the globe, India needs to have a strong, sustained investment in scientific human capital to challenge the future risks related to AMR. The government has initiated varied efforts in identifying and filling gaps in knowledge on the development of new antibiotics and alternatives to existing one to combat AMR. For instance, department of biotechnology (DBT) and Biotechnology Industry Research Assistance Council (BIRAC's) mission to amplify research in the identification of new bacterial targets; call for proposals under the AMR Interdisciplinary Research (AMRIT) Team Grants, to foster collaborative research in AMR and collaboration with UK-based innovation charity organisation, Nesta, to create a pipeline of innovators who can develop a point–of–care diagnostic test to conserve antibiotics for future generations, are some of the progressive steps in fight against AMR. Additionally, ICMR's flagship initiative Antimicrobial Resistance Surveillance & Research Network (AMRSN) to generate high-quality data on AMR trends across India through 30 tertiary care hospitals and research institutions; funding R&D in areas such as rapid diagnostics, novel antimicrobials with international bodies like WHO, CDC (USA), and the Fleming Fund are other examples of India's efforts. Despite these efforts, challenges do persist in providing the much-needed boost in generating a talented workforce of scientists, researchers and innovators to fight against AMR. One of the major systemic challenges facing loss of scientific talent is due to academia–industry leakages. Despite producing highly skilled microbiologists, pharmacologists, and biotechnologists, LMICs like India struggle to retain researchers in the AMR domain due to inadequate funding, limited career pathways and lack of translational research ecosystems. Additionally, limited interest from the industry to invest in providing hands-on training to the emerging talent further amplifies the challenges. To mitigate these challenges, India Pharma Inc. needs to support adequate funding and pull incentives to support the talent eager to work in the field of AMR. The industry and the government must come together to support antimicrobial stewardship programs while ensuring adequate resources, and robust research infrastructure to retain and nurture talent in the larger ecosystem. Government bodies like BIRAC should further intensify their schemes like Biotechnology Ignition Grant (BIG) or Small Business Innovation Research Initiative (SBIRI) to seed innovation and support long-term product development, and market access in AMR. Given the alacrity of challenge at hand, India must focus towards creating a robust pipeline or sustained funding ecosystem for retaining talent instrumental in pushing new breakthrough in antibiotic discovery. Ensuring that we have a workforce of trained research personnel will be crucial for research funding to go as far as possible and yield the most successful results to tackle AMR. This article is authored by Saransh Chaudhary, president, Global Critical Care, Venus Remedies Ltd and CEO, Venus Medicine Research Centre.

Covid cases rise in India: Active caseloads hit 3,961, 4 more deaths; Kerala, Maharashtra, Delhi worst affected
Covid cases rise in India: Active caseloads hit 3,961, 4 more deaths; Kerala, Maharashtra, Delhi worst affected

Time of India

timean hour ago

  • Time of India

Covid cases rise in India: Active caseloads hit 3,961, 4 more deaths; Kerala, Maharashtra, Delhi worst affected

India's active Covid-19 case count climbed to 3,961 on Monday, June 2—up by 566 since Sunday—as Kerala, Maharashtra, and Delhi continued to report the highest number of infections, according to data from the Ministry of Health and Family Welfare (MoHFW). The country has recorded 32 Covid-related deaths since January 1, including four deaths reported in the past 24 hours. Delhi, Kerala, Maharashtra, and Tamil Nadu each logged one covid-related death. The deceased included a 22-year-old woman in Delhi with a history of post-tuberculosis lung disease and a 44-year-old man in Maharashtra suffering from acute respiratory distress and aortic valve issues. Kerala's latest fatality was reported, though details remain pending. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Elegant New Scooters For Seniors In 2024: The Prices May Surprise You Mobility Scooter | Search Ads Learn More Undo Delhi sees sharpest rise again; Tamil Nadu, Karnataka report deaths Delhi reported the sharpest daily increase among major states, adding 47 new active cases and one death. Tamil Nadu, which now has 189 active cases, recorded the death of a 25-year-old man with bronchial asthma and acute tubular injury. Karnataka (253 active cases) also reported a fresh Covid-linked death, while Uttar Pradesh, now with 157 active cases, added two more deaths to its toll. Live Events In total, 16 states and UTs have reported Covid-related fatalities so far this year, though most regions continue to report mild cases and relatively low hospitalisation. Kerala remains worst-hit; Maharashtra, West Bengal follow Kerala continues to bear the heaviest Covid burden, with 1,435 active cases, up from 1,336 the previous day. Maharashtra and Delhi follow with 506 and 483 active cases, respectively. West Bengal has also seen a sharp rise, climbing to 331 active infections. Other states reporting higher caseloads include Karnataka (253), Tamil Nadu (189), Uttar Pradesh (157), Gujarat (338), and Rajasthan (69). Smaller increases were also observed in states like Madhya Pradesh (23), Haryana (28), and Odisha (12). A total of 203 patients were discharged across states in the last 24 hours, bringing the total number of recovered or migrated patients this year to 2,188. Experts: No cause for panic, most cases still mild Despite the surge in numbers, health authorities continue to stress that the overall situation remains under control. Most cases are mild and managed under home isolation. The Indian Council of Medical Research (ICMR) and Health Ministry officials have reiterated that there is no immediate cause for alarm, though they urge the public to stay vigilant. 'We have been closely monitoring the situation. At this moment, overall, we should monitor, be vigilant but there is no cause to worry,' said Dr Rajiv Behl, Director General of ICMR. The increase comes amid the spread of Omicron sub-variants LF.7, XFG, JN.1, and NB.1.8.1, recently detected through genome sequencing in western and southern India. The World Health Organization has labelled these 'Variants Under Monitoring,' indicating they currently pose no global threat. Hospital readiness, vaccination, and masking key to managing spread As a precaution, state health departments—especially in Delhi, Maharashtra, and Kerala—are rechecking hospital preparedness and medical supply chains. Authorities are encouraging mask use in crowded or poorly ventilated areas, especially for the elderly and those with comorbidities. With the virus spreading primarily through new sub-variants that are more contagious but less virulent, experts believe vaccination, timely diagnosis, and responsible behaviour will be crucial in keeping hospitalisation and deaths low. While India's caseload remains a fraction of earlier waves, the recent spike—tenfold in under two weeks—has refocused attention on active monitoring, genome sequencing, and public awareness to prevent another full-blown wave.

India Reports 3,961 Active Covid-19 Cases; When Should You Test For Covid? Health Ministry Shares Guidelines
India Reports 3,961 Active Covid-19 Cases; When Should You Test For Covid? Health Ministry Shares Guidelines

NDTV

timean hour ago

  • NDTV

India Reports 3,961 Active Covid-19 Cases; When Should You Test For Covid? Health Ministry Shares Guidelines

India has reported a total of 3,961 active Covid-19 cases so far. According to the Ministry of Health and Family Welfare data, 203 fresh infections were recorded in the last 24 hours. Kerala has reported the most cases, with 1,435, followed by Maharashtra with 506 and Delhi with 483 cases. Four people have succumbed to the virus during the ongoing resurgence of Covid-19. The new highly transmissible variant NB.1.8.1, descendants of the JN.1 variant has contributed to a surge in Covid-19 cases. The JN.1 variant and its related descendants belong to the Omicron family. Along with NB.1.8.1, the LF.7 strain is also circulating rapidly. Symptoms of NB.1.8.1 According to the Centers for Disease Control and Prevention (CDC), the NB.1.8.1 strain has triggered a sharp rise in hospitalisations across China and has also been detected in the United States. Symptoms are generally mild to moderate. However, elderly and immune-compromised people remain at higher risk for severe disease. NB.1.8.1 may not cause severe illness, however, it spreads faster than other variants. Do you need a covid test? Covid cases are rising and so are flu cases, the need for covid testing has become more important than ever. Do you really need a covid test? Here are the health ministry guidelines you should follow. "All individuals need not be tested, because disease is primarily reported in individuals with travel history to the affected countries or close contacts of positive cases," mentions the health ministry. According to the health ministry, all symptomatic people need a covid test if: You have a history of international travel in the last 14 days You came in contact with confirmed cases You are a healthcare provider You are hospitalized patients with Severe Acute Respiratory Illness (SARI) influenza-like illness (ILI) or severe pneumonia. "Asymptomatic direct and high-risk contacts of confirmed cases should be tested once between day 5 and day 14 of coming in his/her contact," the health ministry mentions. Direct and high-risk contact includes those living in the same household with a confirmed case and healthcare workers who examined a confirmed case without adequate protection as per WHO recommendations. Disclaimer: This content including advice provides generic information only. It is in no way a substitute for a qualified medical opinion. Always consult a specialist or your own doctor for more information. NDTV does not claim responsibility for this information.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store